Trial intelligence / Profile preview

MK-1029 dose-ranging study in adults with persistent asthma

2012-000643-27Phase 2Terminated

Sponsor
Merck & Co.
Start
Jul 2012
Modality
Small Molecules
Countries
1
01

Overview

A Phase 2 trial of MK-1029 in persistent asthma, allergic asthma, sponsored by Merck & Co.. Started Jul 2012; status: terminated.

02

Drugs

MK-1029
03

Conditions

persistent asthmaallergic asthma

Beyond the preview

Go deeper on 2012-000643-27.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2012-000643-27.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call